Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066324 · ClinicalTrials.gov registry record
Urine Sample Collection From FOP Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 25
- Enrollment target
NCT02066324 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT02066324 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to collect urine samples from patients with fibrodysplasia ossificans progressiva (FOP) for the assessment of biomarkers related to disease, disease progression and for prediction of flare-ups of the disease. Disease related biomarkers in these patients are currently unknown. This study aims to support the development of novel therapy/ies for this disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02066324
The ClinicalTrials.gov registry entry for NCT02066324 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02066324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02066324 about?
NCT02066324 is a clinical study titled "Urine Sample Collection From FOP Patients". The purpose of this study is to collect urine samples from patients with fibrodysplasia ossificans progressiva (FOP) for the assessment of biomarkers related to disease, disease progression and for prediction of flare-ups of the disease. Disease related biomarkers in these patients are currently unk...
What is the current status of trial NCT02066324?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2013-11. Estimated completion is 2014-08.
Who is sponsoring clinical trial NCT02066324?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.